Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Publication Date
2024
Content Type
Article
PubMed ID:
Citation
Journal of Clinical Oncology (2024) 42(24):2928-2938